Cystic Fibrosis Screening

 Screening the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene for common mutations is now routinely performed in many molecular genetics laboratories.

ELUCIGENE™ CF -HT v.2

	Detects 30 of the most common CFTR mutations     found in Caucasian populations plus the intron 8     polymorphism 5T/7T/9T (poly T)
	Poly T reporting can be easily switched on or off as     required.
	Includes all mutations approved by ACOG/ACMG for US cystic fibrosis screening.
	Detects wildtype and mutant alleles at all loci (i.e. full genotyping)

CF 29
ELUCIGENE CF29 has been developed to provide laboratories with a simple and accurate means of routinely testing 29 of the most prevalent mutations in individuals of European Caucasian descent. Genotype information for ΔF508 makes the test highly valuable in both disease diagnosis and screening applications.

CF Poly-T    
Analysis of the polythymidine tract in intron 8 of the CFTR gene is of particular clinical significance when the R117H mutation is identified. ELUCIGENE CF Poly-T is separately available for the analysis of the polythymidine tract to allow total flexibility of choice for Poly-T testing in CF screening programs.

CF-MEP
ELUCIGENE CF-MEP detects five mutations in the CFTR gene that are particularly common in Sephardic Jews of middle-eastern origin. When used together with ELUCIGENE CF7 a total of eleven different mutations can be identified giving an excellent coverage in Jews of various ethnic backgrounds.

TRP 
The ELUCIGENE TRP (Thrombosis Risk Panel) provides laboratories with a simple and accurate means of routinely testing for the three most relevant mutations implicated in the risk of developing venous thromboembolism.

The factor V Leiden (R506Q) mutation is the most common inherited form of thrombophilia, but the Prothrombin 20210A (factor II) and MTHFR (methylenetetrahyrofolate reductase) C677T also contribute toward increased risk. 

ashkenazi